16 results
424B5
PRTA
Prothena Corporation plc
24 Mar 21
Prospectus supplement for primary offering
4:01pm
in VITAL (hazard ratio (HR)=0.413, p=0.025, over 9 months).
The significant survival benefit observed in VITAL with birtamimab was further supported … progression on MDS-UPDRS Part III vs. placebo over one year, with a hazard ratio of 0.82 (pooled dose levels).
Prasinezumab was found to be generally safe
424B5
PRTA
Prothena Corporation plc
23 Mar 21
Prospectus supplement for primary offering
5:13pm
in the control group in VITAL (hazard ratio (HR)=0.413, p=0.025, over 9 months).
The significant survival benefit observed in VITAL with birtamimab … to at least a 5-point progression on MDS-UPDRS Part III vs. placebo over one year, with a hazard ratio of 0.82 (pooled dose levels).
Prasinezumab
8-K
EX-99.1
7v8ui2dh6gwqtit4v an
1 Feb 21
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
4:16pm
8-K
EX-99.1
u4ls2om4 8pbx9zw0sf
7 May 19
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
4:09pm
8-K
EX-99.1
nueb6f0v92xwh40pg
18 Apr 19
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
4:06pm
10-12B/A
EX-10.6
ogeq0u 3mpltkbf
30 Nov 12
Registration of securities (amended)
12:00am
- Prev
- 1
- Next